SCHEMBL2293802

SCHEMBL2293802

NNC(=O)c1ccccc1I

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.60
KMT2A Q03164 3/20 0.60
TDP1 Q9NUW8 2/20 0.60
CTSD P07339 2/20 0.53
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
CA9 Q16790 1/20 0.53
ALDH1A1 P00352 3/20 0.52
GAA P10253 2/20 0.48
MAPT P10636 2/20 0.48
MITF O75030 1/20 0.48
NCOA1 Q15788 1/20 0.48
NCOA3 Q9Y6Q9 1/20 0.48
P2RX7 Q99572 1/20 0.47
SIGMAR1 Q99720 1/20 0.44
PARP1 P09874 1/20 0.44
ABL1 P00519 1/20 0.43
SRC P12931 1/20 0.43
GFER P55789 2/20 0.42
MAOB P27338 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30547074 0.84 CTSD (0.63) MEN1KMT2ATDP1CTSDCA1
SCHEMBL239328 0.84 CTSD (0.63) MEN1KMT2ATDP1CTSDCA1
Hydroxyamine SCHEMBL14300671 0.81 CTSD (0.61) MEN1KMT2ATDP1CTSDCA1
Hydrazine SCHEMBL14300720 0.81 CTSD (0.61) MEN1KMT2ATDP1CTSDCA1
Hydrochloric Acid SCHEMBL6692325 0.81 CTSD (0.61) MEN1KMT2ATDP1CTSDCA1
SCHEMBL27583795 0.80 MEN1 (0.62) MEN1KMT2ATDP1CA9ALDH1A1
SCHEMBL15417609 0.79 MEN1 (0.61) MEN1KMT2ATDP1CA1CA9
SCHEMBL11325406 0.79 KMT2A (0.51) MEN1KMT2ATDP1SIGMAR1PARP1
SCHEMBL13667371 0.79 MEN1 (0.51) MEN1KMT2ATDP1SIGMAR1MAOB
SCHEMBL8814831 0.79 KMT2A (0.51) MEN1KMT2ATDP1SIGMAR1PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113416266-A Aromatic hydrazide compound-cyclodextrin inclusion compound and preparation method thereof 湖北工业大学 2021-09-21 CN claimed
CN-111848598-B Heterocyclic compound, application thereof and composition containing same 健艾仕生物医药有限公司 2024-12-10 CN disclosed
CN-117157338-A Polymer latex composition 昕特玛私人有限公司 2023-12-01 CN disclosed
CN-116941616-A Application of narinone derivative in preparing medicine for preventing and treating plant pathogenic fungi 贵州省天然产物研究中心 2023-10-27 CN disclosed
US-11136301-B2 Broad spectrum antiviral compounds and uses thereof The Regents of the University of California, A California Corporation et al. (US) 2021-10-05 US disclosed
US-11136301-B2 Broad spectrum antiviral compounds and uses thereof The Regents of the University of California, A California Corporation et al. (US) 2021-10-05 US disclosed
CN-113416266-A Aromatic hydrazide compound-cyclodextrin inclusion compound and preparation method thereof 湖北工业大学 2021-09-21 CN disclosed
CN-111848598-A Heterocyclic ring-containing compound, application thereof and composition containing heterocyclic ring-containing compound 健艾仕生物医药有限公司 2020-10-30 CN disclosed
WO-2020216378-A1 HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME 健艾仕生物医药有限公司 2020-10-29 WO disclosed
US-20180297963-A1 BROAD SPECTRUM ANTIVIRAL COMPOUNDS AND USES THEREOF THE UNIVERSITY OF MIAMI 2018-10-18 US disclosed
WO-2012110860-A1 TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS GLENMARK PHARMACEUTICALS S.A. (CH) 2012-08-23 WO disclosed
EP-2163554-B1 PYRIMIDODIAZEPINONE DERIVATIVE KYOWA HAKKO KIRIN CO LTD (JP) 2012-08-01 EP disclosed
US-7998954-B2 Pyrimidodiazepinone derivative KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-08-16 US disclosed
US-20100190775-A1 PYRIMIDODIAZEPINONE DERIVATIVE KYOWA HAKKO KIRIN CO., LTD (JP) 2010-07-29 US disclosed
EP-2163554-A1 PYRIMIDODIAZEPINONE DERIVATIVE Kyowa Hakko Kirin Co., Ltd. (JP) 2010-03-17 EP disclosed
EP-1809332-A2 COMPOSITIONS FOR MULTI-STEP DELIVERY OF HOT-SPOTS RADIATION TO CANCER CELLS Oncologic, Inc. (US) 2007-07-25 EP disclosed
WO-2006010165-A2 COMPOSITIONS FOR MULTI-STEP DELIVERY OF HOT-SPOTS RADIATION TO CANCER CELLS ONCOLOGIC, INC. (US) 2006-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11136301-B2 Broad spectrum antiviral compounds and uses thereof MAVS, EIF2AK2, ZC3HAV1 MEN1 4609/4885KMT2A 3809/4885TDP1 582/4885
US-20100190775-A1 PYRIMIDODIAZEPINONE DERIVATIVE KCNJ1, KCNJ11, ADRA1D MEN1 765/4885KMT2A 434/4885TDP1 3286/4885
US-20180297963-A1 BROAD SPECTRUM ANTIVIRAL COMPOUNDS AND USES THEREOF MAVS, EIF2AK2, ZC3HAV1 MEN1 4609/4885KMT2A 3809/4885TDP1 582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.